Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection
Parés-Badell, Oleguer (Hospital Universitari Vall d'Hebron)
Martínez Gómez, Xavier (Hospital Universitari Vall d'Hebron)
Pinós Tella, Laia (Hospital Universitari Vall d'Hebron)
Borras Bermejo, Blanca (Hospital Universitari Vall d'Hebron)
Uriona, Sonia (Hospital Universitari Vall d'Hebron)
Otero-Romero, Susana (Hospital Universitari Vall d'Hebron)
Rodrigo-Pendás, José Ángel (Hospital Universitari Vall d'Hebron)
Cossio, Yolima (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Agustí Escasany, M. Antònia (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Aguilera, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Campins Martí, Magda (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública

Data:	2021
Resum:	The aim of this study was to assess adverse reactions to COVID-19 vaccines, comparing the BNT162b2 or the mRNA-1273 COVID-19 vaccines and the presence and seriousness of a previous COVID-19 infection. We conducted a cross-sectional online survey of vaccinated healthcare workers at a tertiary hospital in Barcelona (Spain). Thirty-eight percent of vaccine recipients responded to the questionnaire. We compared the prevalence of adverse reactions by vaccine type and history of COVID-19 infections. A total of 2373 respondents had received the BNT162b2 vaccine, and 506 the mRNA-1273 vaccine. The prevalence of at least one adverse reaction with doses 1 and 2 was 41% and 70%, respectively, in the BNT162b2 group, and 60% and 92% in the mRNA-1273 group (p < 0. 001). The BNT162b2 group reported less prevalence of all adverse reactions. Need for medical leave was significantly more frequent among the mRNA-1273 group (12% versus 4. 6% p < 0. 001). Interestingly, respondents with a history of allergies or chronic illnesses did not report more adverse reactions. The frequency of adverse reactions with dose 2 was 96% (95% CI 88-100%) for those with a history of COVID-19 related hospitalization, and 86% (95% CI 83-89%) for those with mild or moderate symptomatic COVID-19, significantly higher than for participants with no history of COVID-19 infections (67%, 95% CI 65-69%). Our results could help inform vaccine recipients of the probability of their having adverse reactions to COVID-19 vaccines.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	SARS-CoV-2 ; COVID-19-vaccination ; Mrna vaccines ; Adverse reactions ; Healthcare workers
Publicat a:	Vaccines (Basel), Vol. 9, Num. 12 (december 2021) , ISSN 2076-393X

DOI: 10.3390/vaccines9121463
PMID: 34960209

9 p, 1.7 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats